Neurotech advances NTI164 into pivotal Phase 3 autism testing

Beyond Harmony enters pivotal testing

Neurotech International Limited (ASX:NTI) has moved NTI164 into its most consequential clinical test yet, dosing the first patient in the pivotal Phase 3 Beyond Harmony trial for children with autism spectrum disorder. All six Australian sites have been initiated across Victoria, Queensland, New South Wales, Tasmania and Western Australia, with up to 200 participants planned under a randomised, double-blind, placebo-controlled adaptive design.

The trial is intended to assess efficacy, safety and tolerability, with a focus on core ASD symptoms and behavioural and functional outcomes. Neurotech said it had received more than 300 enquiries from parents and caregivers after media coverage of the study, which it described as providing confidence in recruitment within the planned timeframe. That interest is not the same as enrolment, however, and the filing does not report a recruitment total beyond the first patient dosed.

Earlier Harmony data now support the Phase 3 program

Beyond Harmony builds on the 54-patient Phase II/III Harmony study, whose results were published in the peer-reviewed journal Neurotherapeutics during the quarter. Neurotech said the study produced clinically meaningful and statistically significant results across a range of validated measures, alongside a favourable safety profile. Those findings come from the earlier study and do not constitute Phase 3 evidence; the new trial is designed to generate the pivotal efficacy and safety data needed for future regulatory submissions.

The company had already reached the pivotal-stage milestone in its x

FDA clearance opens a US development pathway

The US Food and Drug Administration cleared Neurotech’s Investigational New Drug submission for NTI164, authorising the proposed US clinical development program. Neurotech said any US study would comprise a population pharmacokinetic program intended to complement the Australian Phase 3 trial by generating data on dose characterisation and supporting future registration work.

Clearance creates a formal US pathway, but the filing does not say that Neurotech has begun the US study. The company is also engaging with the Australian Therapeutic Goods Administration on aligning its Australian and US regulatory strategies. Separately, the US Patent and Trademark Office issued Notices of Allowance for two applications covering methods of reducing neuroinflammation with NTI164 and methods of treating ASD.

Funding improved, but the cash cushion remains narrow

Neurotech finished the quarter with approximately $5.2 million in cash and equivalents, up from $2.4 million at the end of the previous quarter. Financing inflows included $3.15 million from a secured loan against anticipated FY2026 and FY2027 refundable R&D tax incentives, while the company also secured binding commitments for an approximately $4.5 million placement of new shares at $0.014 each. The placement had been reported as funding the Phase 3 placement, with about $0.4 million subject to shareholder approval.

The improvement in cash came as operating outflows rose to approximately $4.19 million, compared with $1.9 million in the prior quarter. Research and development accounted for $3.93 million, with the company attributing the increase partly to clinical trial initiation fees and regulatory, manufacturing and preclinical work. On the Appendix 4C calculation, quarter-end cash represented 1.24 quarters of funding at the latest operating outflow rate.

Trial funding depends on execution and incoming cash

Neurotech said it expects operating outflows to fall from the second quarter because the initial clinical trial initiation payments were one-off costs. It also expects the second placement tranche and further R&D tax incentive funds, net of debt repayment, to provide additional liquidity. The secured loan carries interest of 16% a year plus a capitalised 1% establishment fee and matures on 31 December 2027, subject to an extension option.

On its current clinical plan and budget, the company expects to remain funded through the Phase 3 topline data readout. That expectation depends on the timing and receipt of the outstanding placement proceeds and R&D tax refunds, as well as the trial spending profile staying broadly within plan. The next meaningful evidence will therefore come from two tracks at once: recruitment and interim progress in Beyond Harmony, and whether cash burn moderates as management forecasts.